Eton Pharmaceuticals appoints Ipek Erdogan-Trinkaus as CCO; cites Increlex closing and ET-400 launch

Eton Pharmaceuticals, Inc.

Ipek Erdogan-Trinkaus appointed Chief Commercial Officer, effective December 3, 2024.
She previously served as GM of Pediatric Endocrinology at Tolmar, leading the FENSOLVI® launch.
CEO Sean Brynjelsen highlights role at a critical time with Increlex closing in late-December and ET-400 launch in early 2025.
Erdogan-Trinkaus brings rare disease commercial experience from Tolmar and other health/wellness companies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.